Citagem Indications/Uses

Ovarian cancer: In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months following platinum-based therapy.
Breast cancer: In combination with paclitaxel, for the first-line treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior therapy should have included an anthracycline, unless clinically contraindicated.
Non-small cell lung cancer (NSCLC): Alone or in combination with cisplatin, for the first-line treatment of patients with inoperable, locally advanced (inoperable stage IIIA or IIIB) or metastatic (stage IV) NSCLC. Monotherapy may be considered in elderly patients or those with performance status 2.
Pancreatic cancer: For the first-line treatment of adult patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. It can be used as first-line therapy or second-line therapy in patients with 5-fluorouracil-refractory pancreatic cancer.
Bladder cancer: In combination with cisplatin, for the treatment of advanced transitional cell bladder cancer (muscle invasive stage IV tumors with or without metastases).